Fc Engineered Anti-CD19 Monoclonal Antibodies with Enhanced In Vitro Efficacy Against Multiple Lymphoma Cell Lines.

@inproceedings{Zhukovsky2006FcEA,
  title={Fc Engineered Anti-CD19 Monoclonal Antibodies with Enhanced In Vitro Efficacy Against Multiple Lymphoma Cell Lines.},
  author={Eugene A. Zhukovsky and Seung Y. Chu and Matthew J. Bernett and Philip W. Hammond and Sher Karki and Wei Dang and Collin Edler and Nephi Polder and Cheryl Chan and Jonathan M Jacinto and John R. Desjarlais},
  year={2006}
}
CD19 is a pan-B cell surface receptor that is expressed from early stages of pre-B cell development through terminal differentiation into plasma cells. It is an attractive immunotherapy target for cancers of lymphoid origin since it is also expressed on the vast majority of Non-Hodgkin Lymphoma (NHL) cells. Although the anti-CD20 monoclonal antibody rituximab is efficacious for the treatment of lymphoid tumors, a growing population of rituximab-refractory patients has resulted in an unmet need… CONTINUE READING